Alai Tan1, Brent Sullenbarger1, Ruchika Prakash2, Jodi C McDaniel3. 1. College of Nursing, The Ohio State University, USA. 2. Department of Psychology, The Ohio State University, USA. 3. College of Nursing, The Ohio State University, USA. Electronic address: mcdaniel.561@osu.edu.
Abstract
BACKGROUND: High levels of circulating proinflammatory cytokines are characteristic of inflammaging, a term coined to describe age-related chronic systemic inflammation involved in the etiology of many age-related disorders including nonhealing wounds. Some studies have shown that supplementing diets with n-3 polyunsaturated fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) lowers systemic levels of key proinflammatory cytokines associated with inflammaging. However, findings from the few studies that have focused exclusively on older adults are inconclusive. As such, the objective of this randomized controlled study was to test the effects of EPA+DHA therapy on circulating levels of proinflammatory cytokines in adults in middle to late adulthood. METHODS:Plasma levels of fatty acids and interleukin (IL)-6, IL-1β and tumor necrosis factor-α (TNF-α) were measured in 35 participants with chronic venous leg ulcers (mean age: 60.6 years) randomnly assigned to 8 weeks of EPA+DHA therapy (2.5 g/d) or placebo therapy. RESULTS:EPA+DHA therapy had a significant lowering effect on levels of IL-6, IL-1β and TNF-α after 4 weeks of therapy and an even greater lowering effect after 8 weeks of therapy. Further, after adjusting for baseline difference, the treatment group had significantly lower levels of IL-6 (p = 0.008), IL-1β (p < 0.001), and TNF-α (p < 0.001) at Week 4 and at Week 8 [IL-6 (p = 0.007), IL-1β (p < 0.001), and TNF-α (p < 0.001)] compared to the control group. CONCLUSION:Adults in middle to late adulthood receiving EPA+DHA therapy demonstrated significantly greater reductions in circulating levels of proinflammatory cytokines compared with those receiving placebo therapy. EPA+DHA therapy may be an effective low-risk dietary intervention for assuaging the harmful effects of inflammaging.
RCT Entities:
BACKGROUND: High levels of circulating proinflammatory cytokines are characteristic of inflammaging, a term coined to describe age-related chronic systemic inflammation involved in the etiology of many age-related disorders including nonhealing wounds. Some studies have shown that supplementing diets with n-3 polyunsaturated fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) lowers systemic levels of key proinflammatory cytokines associated with inflammaging. However, findings from the few studies that have focused exclusively on older adults are inconclusive. As such, the objective of this randomized controlled study was to test the effects of EPA+DHA therapy on circulating levels of proinflammatory cytokines in adults in middle to late adulthood. METHODS: Plasma levels of fatty acids and interleukin (IL)-6, IL-1β and tumor necrosis factor-α (TNF-α) were measured in 35 participants with chronic venous leg ulcers (mean age: 60.6 years) randomnly assigned to 8 weeks of EPA+DHA therapy (2.5 g/d) or placebo therapy. RESULTS:EPA+DHA therapy had a significant lowering effect on levels of IL-6, IL-1β and TNF-α after 4 weeks of therapy and an even greater lowering effect after 8 weeks of therapy. Further, after adjusting for baseline difference, the treatment group had significantly lower levels of IL-6 (p = 0.008), IL-1β (p < 0.001), and TNF-α (p < 0.001) at Week 4 and at Week 8 [IL-6 (p = 0.007), IL-1β (p < 0.001), and TNF-α (p < 0.001)] compared to the control group. CONCLUSION: Adults in middle to late adulthood receiving EPA+DHA therapy demonstrated significantly greater reductions in circulating levels of proinflammatory cytokines compared with those receiving placebo therapy. EPA+DHA therapy may be an effective low-risk dietary intervention for assuaging the harmful effects of inflammaging.
Authors: Janice K Kiecolt-Glaser; Martha A Belury; Kyle Porter; David Q Beversdorf; Stanley Lemeshow; Ronald Glaser Journal: Psychosom Med Date: 2007-03-30 Impact factor: 4.312
Authors: Joyce Faber; Marloes Berkhout; Arjan P Vos; John W C Sijben; Philip C Calder; Johan Garssen; Ardy van Helvoort Journal: J Nutr Date: 2011-03-23 Impact factor: 4.798
Authors: Aoife O'Donovan; Matthew S Pantell; Eli Puterman; Firdaus S Dhabhar; Elizabeth H Blackburn; Kristine Yaffe; Richard M Cawthon; Patricia L Opresko; Wen-Chi Hsueh; Suzanne Satterfield; Anne B Newman; Hilsa N Ayonayon; Susan M Rubin; Tamara B Harris; Elissa S Epel Journal: PLoS One Date: 2011-05-13 Impact factor: 3.240
Authors: Hylde Zirpoli; Chuchun L Chang; Yvon A Carpentier; Adina T Michael-Titus; Vadim S Ten; Richard J Deckelbaum Journal: Annu Rev Nutr Date: 2020-09-23 Impact factor: 11.848
Authors: Lee B Bockus; Mary L Biggs; Heidi T M Lai; Marcia C de Olivera Otto; Amanda M Fretts; Barbara McKnight; Nona Sotoodehnia; Irena B King; Xiaoling Song; David S Siscovick; Dariush Mozaffarian; Rozenn N Lemaitre Journal: JAMA Netw Open Date: 2021-08-02
Authors: Massimiliano Ruscica; Alberto Corsini; Nicola Ferri; Maciej Banach; Cesare R Sirtori Journal: Pharmacol Res Date: 2020-05-20 Impact factor: 7.658
Authors: Denisa Margină; Anca Ungurianu; Carmen Purdel; George Mihai Nițulescu; Dimitris Tsoukalas; Evangelia Sarandi; Maria Thanasoula; Tatyana I Burykina; Fotis Tekos; Aleksandra Buha; Dragana Nikitovic; Demetrios Kouretas; Aristidis Michael Tsatsakis Journal: Food Chem Toxicol Date: 2020-07-05 Impact factor: 6.023
Authors: Licínia Ganança; Hanga C Galfalvy; Sebastian Cisneros-Trujillo; Zahra Basseda; Thomas B Cooper; Xinguo Ren; Maria Luisa Figueira; Maria A Oquendo; J John Mann; M Elizabeth Sublette Journal: J Psychiatr Res Date: 2020-12-17 Impact factor: 4.791